111, Inc. announced that Mr. Anfeng Guo, a former Vice President of Oncology Business Unit at Bristol Myers Squibb, is appointed as Chief Innovation Officer, effective May 1, 2020. In his new position, Mr. Guo will oversee operation and innovation of internet medical platform across the company. He will also manage Hanhong Pharmaceutical Co. Ltd., a wholly owned subsidiary of 111, to further pursue the endeavors of the company in the commercialization of innovative drugs, especially cancer drugs and relevant consumables and equipment. Prior to joining 111, he was the Vice President of both Oncology Business Unit and Virology Business Unit at Bristol Myers Squibb, creating China's first excellent immuno-oncology sales team. Under his leadership, the Virology Business Unit at Bristol Myers Squibb realized a V-shaped reversal with dominant share in the immune-oncology market.